Evidence map›Paper›PMID 32382660›Full record

ArticleHealth science reports2020

Analysis of

Christian S Alvarez, Jeremy Ortiz, Giovanna Bendfeldt-Avila, Yi Xie, Mingyi Wang, Dongjing Wu, Herbert Higson, Elisa Lee, Kedest Teshome, Joaquin Barnoya and 6 more

Open access · goldAbstract read
In one paragraph

Article in Health science reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Analysis ofHealth science reports · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 2 countries.

Christian S AlvarezDivision of Cancer Epidemiology and Genetics National Cancer Institute Bethesda Maryland.ORCID https://orcid.org/0000-0002-5338-0444
Jeremy OrtizInstituto de Cancerología/INCAN Guatemala City Guatemala.
Giovanna Bendfeldt-AvilaHospital Centro Médico Militar Guatemala City Guatemala.
Yi XieDivision of Cancer Epidemiology and Genetics National Cancer Institute Bethesda Maryland.
Mingyi WangCancer Genetics Research Laboratory, Division of Cancer Epidemiology and Genetics, Leidos Biomedical Research Inc Frederick National Laboratory for Cancer Research Gaithersburg Maryland.
Dongjing WuCancer Genetics Research Laboratory, Division of Cancer Epidemiology and Genetics, Leidos Biomedical Research Inc Frederick National Laboratory for Cancer Research Gaithersburg Maryland.
Herbert HigsonCancer Genetics Research Laboratory, Division of Cancer Epidemiology and Genetics, Leidos Biomedical Research Inc Frederick National Laboratory for Cancer Research Gaithersburg Maryland.
Elisa LeeCancer Genetics Research Laboratory, Division of Cancer Epidemiology and Genetics, Leidos Biomedical Research Inc Frederick National Laboratory for Cancer Research Gaithersburg Maryland.
Kedest TeshomeCancer Genetics Research Laboratory, Division of Cancer Epidemiology and Genetics, Leidos Biomedical Research Inc Frederick National Laboratory for Cancer Research Gaithersburg Maryland.
Joaquin BarnoyaIntegra Cancer Institute Guatemala City Guatemala.
David E KleinerLaboratory of Pathology Center for Cancer Research, NCI, NIH Bethesda Maryland.
John D GroopmanDepartment of Environmental Health and Engineering, Bloomberg School of Public Health Johns Hopkins University Baltimore Maryland.
Roberto OrozcoDepartment of Pathology Hospital General San Juan de Dios Guatemala City Guatemala.
Katherine A McGlynnDivision of Cancer Epidemiology and Genetics National Cancer Institute Bethesda Maryland.
Eduardo GharzouziIntegra Cancer Institute Guatemala City Guatemala.
Michael DeanDivision of Cancer Epidemiology and Genetics National Cancer Institute Bethesda Maryland.
Leidos (United States) · USNational Cancer Institute · USLiga Nacional Contra el Cáncer · GTHospital General San Juan de Dios · GTCenter for Cancer Research · USJohns Hopkins University · US

Funding

Studies of Rare CancersZIACP010158 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI MCGLYNN, KATHERINE · 2009 to 2025
$19.1M
Postmortem PathologyZICBC010685 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KLEINER, DAVID ERWIN · 2009 to 2025
$14.3M
6 · The paper itself

Abstract

BACKGROUND AND

aimsGuatemala has the highest incidence of hepatocellular carcinoma (HCC) in the Western hemisphere. The major risk factors in Guatemala are not well characterized, but the prevalence of hepatitis B virus (HBV) and hepatitis C virus (HCV) appears to be low, while the prevalence of aflatoxin (AFB

methodsFormalin-fixed, paraffin-embedded (FFPE) HCC tissues were obtained from three hospitals in Guatemala City between 2016 and 2017. In addition, tumor tissues preserved in RNAlater were also obtained. Sociodemographic and clinical information including HBV and HCV status were collected. Targeted sequencing of

resultsNinety-one FFPE tissues were examined, from 52 men and 39 women. Median (IQR) age at diagnosis was 62 (51-70). Among those with known HBV and HCV status, two were HBV+ and three were HCV+. Overall, 47% of the HCCs had a

conclusionsThe presence of the

Indexed as

aflatoxinGuatemalahepatocellular carcinomaR249S mutationTP53 mutation

Identifiers

PMID32382660
PMCPMC7202218
OpenAlexW3023454748

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.